Abstract
The objective of this study was to verify the effect of certain new biocompatible additive on the stability and feasibility of the SLN using Glyceryl monostearate as lipid matrix. Cationic Starch, which is newly modified in organic chemistry laboratories, used with different ratios to show the effect on zeta potential of formulated nanoparticles using Triamcinolone acetonide as a model drug. Method of High shear homogenization was used for preparation of SLN utilizing a rotor-stator homogenizer. It was found that particle diameter of formulated nanoparticles shifted from nanosized to micronized with increase of amount of cationic starch used (2.5 to 10% w/w), while the zeta potential reduced although showing high negative values (-36 to -27 mV), indicating stability. The loading capacity and encapsulation efficiency of produced nanoparticles were reduced with increase of amount of cationic starch used. The influence of cationic starch on drug release from prepared formulae was studied using dialysis bag technique. Fourier Transformation Infrared Spectroscopy (FTIR) showed the absence of new bands for loaded solid lipid nanoparticles indicating no interaction between drug and cationic starch. Electron microscope of scanning technique indicated sphere form of prepared solid lipid nanoparticles with smooth surface. It was concluded that retardation of in vitro release and effect on simulated in vivo permeation through human skin were affected by using different concentrations of cationic starch as excipient that meantime, be used to reduce zeta potential and act as self-flocculating agent during formulation.